drugset / Trial / NCT02717962
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of O-6-methylguanine-DNA methyltransferase (MGMT) unmethylated glioblastoma with VAL-083 improves overall survival (OS), compared to historical control, in the adjuvant or recurrent setting.
Timeline
- Start
- 2017-01-20
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dianhydrogalactitol | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Dianhydrogalactitol | Other / unclassified | 40 mg/m2 | Intravenous |